Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil

References

• Stewart BJ, Kleihues P. World Cancer Report. IARC Press, Lyon 2003
   Google Scholar
• Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2006: Incidência de Câncer no Brasil. Accessed 5 July 2007 from: http://www.inca.gov.br/estimativa/2006/.
   Google Scholar
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. Journal of Clinical Oncology 1992; 10: 896–903.
   Google Scholar
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. Journal of Clinical Oncology 1998; 16: 301–308.
   PubMedGoogle Scholar
• Saad ED, Hoff PM. Chemotherapy of metastatic colorectal cancer. Current Treatment Options in Gastroenterology 2005; 8: 239–247.
   Google Scholar
• Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Journal of Clinical Oncology 2001; 19: 2282–2292.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. Journal of Clinical Oncology 2001; 19: 4097–4106.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New England Journal of Medicine 2000; 343: 905–914.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2004; 22: 23–30.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004; 350: 2335–2342.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine 2004; 351: 337–345.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology 2007; 25: 1658–1664.
   PubMed Web of Science ®Google Scholar
• Kelly C, Cassidy J. Capecitabine in the treatment of colorectal cancer. Expert Reviews in Anticancer Therapy 2007; 7: 803–810.
   Web of Science ®Google Scholar
• Terstriep S, Grothey A. First- and second-line therapy of metastatic colorectal cancer. Expert Reviews in Anticancer Therapy 2006; 6: 921–930.
   Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement) 2007; 3510.
   Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E, et al. First efficacy and safety results from XELOX-1/NO 16966, a randomized 2x2 factorial Phase III trial of XELOX vs. FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (mCRC). Annals of Oncology 2006; 17, (Suppl 9, late breaking abstract 3).
   Google Scholar
• Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 2007, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4030.
   Google Scholar
• Perrocheau G, Bennouna J, Ducreux M, et al. Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (mCRC) in the French setting. Journal of Clinical Oncology 2007, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4083.
   Google Scholar
• Schrag D. The price tag on progress – chemotherapy for colorectal cancer. New England Journal of Medicine 2004; 351: 317–319.
   PubMed Web of Science ®Google Scholar
• Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies. Practical applications and methodological shortcomings. Pharmacoeconomics 1997; 12: 121–129.
   PubMed Web of Science ®Google Scholar
• Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technology Assessment 1998; 2: i–iv; 1–88.
   PubMedGoogle Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinical Oncology 2004; 22: 229–237.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. Journal of Clinical Oncology 2004; 22: 2084–2091.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Di Bartolomeo M, Mariani L, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279–287.
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Journal of Clinical Oncology 2005; 23: 246S, (Suppl, late breaking abstract 3500).
   Google Scholar
• Guia Farmacêutico Brasíndice, Novembro 2006. São Paulo: Andrei Publicações Médicas, Farmacêuticas e Técnicas Ltda, 2006.
   Google Scholar
• Associação Médica Brasileira. Classificação Brasileira Hierarquizada de Procedimentos Médicos – CBHPM. Brasília: AMB – Associação Médica Brasileira, 2004.
   Google Scholar
• Revista Simpro, n. 45, 2006.
   Google Scholar
• Programa de Estudos Avançados em Administração Hospitalar e de Sistemas de Saúde - PROAHSA. Composição dos custos hospitalares. Indicadores PROAHSA. 41, 2006.
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, Oxford 2005
   Google Scholar
• Manual Geral de Condutas SBOC (16/11/2007). Available at http://www.sboc.org.br/ [in portuguese].
   Google Scholar
• Wiseman LR, Lyseng-Williamson KA. Management of metastatic colorectal cancer: defining the role of capecitabine. Disease Management & Health Outcomes 2005; 13: 137–149.
   Google Scholar
• Matasar MJ, Sundararajan V, Grann VR, et al. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs & Aging 2004; 21: 113–133.
   PubMed Web of Science ®Google Scholar
• Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. Journal of Clinical Oncology 1997; 15: 110–115.
   PubMed Web of Science ®Google Scholar
• Jansman FG, Postma MJ, van Hartskamp D, et al. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Clinical Therapy 2004; 26: 579–589.
   PubMed Web of Science ®Google Scholar
• Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a Phase III trial conducted in patients with advanced colorectal carcinoma. European Journal of Cancer 2001; 37: 597–604.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Cassidy J, Figer A, et al. A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (mCRC): XELOX vs. FOLFOX4 ± bevacizumab (A). Journal of Clinical Oncology 2007, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4098.
   Google Scholar
• Garrison L, Cassidy J, Saleh M, et al. Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. Journal of Clinical Oncology 2007, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (20 June Supplement), 2007: 4074.
   Google Scholar